Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Gastroesophageal Junction Adenocarcinoma

Aliases
or Gastroesophageal Junction Adenocarcinoma

53 clinical trials

51 products

29 drugs

Clinical trial
A Phase 3, Multi-Center, Double-Blind, Randomized, Efficacy and Safety Study of M108 Monoclonal Antibody Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Status: Recruiting, Estimated PCD: 2027-01-11
Product
Placebo
Product
M108 monoclonal antibody
Product
Oxaliplatin
Product
Capecitabine
Clinical trial
A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Status: Recruiting, Estimated PCD: 2026-06-30
Product
ASP2138
Product
Tislelizumab
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-02-28
Product
Cisplatin
Product
5-FU
Clinical trial
Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-02-07
Product
BI-1607
Clinical trial
A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Trastuzumab deruxtecan
Clinical trial
A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2023-05-01
Product
Taxotere
Product
Docetaxel
Product
Q-1802
Clinical trial
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Status:
Product
DKN-01
Clinical trial
A Phase I/II Clinical Trial to Evaluate the Safety Tolerance and Initial Efficacy of Q-1802 Combined With Standard Treatment in Patients With Gastrointestinal Tumors
Status: Recruiting, Estimated PCD: 2024-08-30
Product
Paclitaxel
Product
Pembrolizumab
Clinical trial
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Status: Completed, Estimated PCD: 2019-07-19
Clinical trial
Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 Expression
Status: Not yet recruiting, Estimated PCD: 2026-03-31
Product
Azenosertib
Product
Trastuzumab Deruxtecan
Clinical trial
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Status: Recruiting, Estimated PCD: 2027-10-31
Drug
Atezolizumab
Drug
Docetaxel
Drug
fluorouracil
Product
Leucovorin
Drug
mFOLFOX6
Clinical trial
A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Lenvatinib
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamide
Clinical trial
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Status: Completed, Estimated PCD: 2023-04-14
Drug
mFOLFOXIRI
Product
Ramucirumab
Product
Blood for angiome profiling
Product
Blood for cfDNA
Clinical trial
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Drug
Adavosertib
Clinical trial
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Status: , Estimated PCD: 2026-01-31
Drug
AN0025
Product
Ipilimumab
Product
Nivolumab
Drug
Tiragolumab
Product
Neoantigen Peptide Vaccine
Clinical trial
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Status: Active (not recruiting), Estimated PCD: 2024-03-29
Product
Elimusertib
Drug
5-FU
Clinical trial
A Single-arm, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemotherapy Followed by Radiotherapy in the Perioperative Treatment of Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-05-01
Product
Camrelizumab + Oxaliplatin + Paclitaxel
Product
Irinotecan
Product
Leucovorin Calcium
Clinical trial
A Phase 2 Trial of Chemotherapy, Pembrolizumab, and Propranolol in Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma Patients
Status: Recruiting, Estimated PCD: 2026-03-30
Drug
FOLFOXIRI
Product
Propranolol
Clinical trial
Phase II Study of Induction FLOT Followed by Neoadjuvant Chemoradiation in Patients With Resectable Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status: Recruiting, Estimated PCD: 2025-04-19
Product
Sequential FLOT
Clinical trial
A Multi-center, Non-randomized, Three-cohort, Phase II Trial of a Modified Triplet Combination of Docetaxel, Oxaliplatin and Fluorouracil for Gastric Cancer With Peritoneal Carcinomatosis and Inoperable Malignant Bowel Obstruction
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-02-03
Product
Avapritinib
Clinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2027-08-01
Product
AgenT-797
Drug
Botensilimab
Product
Balstilimab
Clinical trial
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study
Status: Recruiting, Estimated PCD: 2024-07-31
Product
Trifluridine and Tipiracil
Clinical trial
A Pilot Trial of Pembrolizumab Plus Chemoradiotherapy in Participants With Unresectable Gastroesophageal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-18
Clinical trial
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Status: Recruiting, Estimated PCD: 2026-12-21
Clinical trial
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status: Terminated, Estimated PCD: 2015-12-23
Product
Panitumumab
Clinical trial
A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Status: Terminated, Estimated PCD: 2022-05-19
Product
Regorafenib and Irinotecan
Clinical trial
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2022-09-09
Drug
zolbetuximab
Drug
placebo
Drug
oxaliplatin
Product
FOLFOX
Clinical trial
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3
Status: Recruiting, Estimated PCD: 2027-12-01
Product
CAPOX
Clinical trial
Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)
Status: Active (not recruiting), Estimated PCD: 2026-12-30
Clinical trial
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal/Gastroesophageal Junction Adenocarcinoma (PHOX)
Status: Recruiting, Estimated PCD: 2026-05-30
Drug
Lurbinectedin
Drug
T-VEC
Clinical trial
A Pilot Study of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Status: Completed, Estimated PCD: 2023-01-27
Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Sonidegib
Clinical trial
A Single-arm, Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Sintilimab and CAPEOX as 1L Treatment for Advanced Unresectable or Metastatic G/GEJ Cancer (FUNCTION Research)
Status: Recruiting, Estimated PCD: 2025-12-15
Product
Fruquintinib + Sintilimab + CAPEOX
Clinical trial
A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia
Status: Active (not recruiting), Estimated PCD: 2022-03-18
Drug
carboplatin
Drug
paclitaxel
Clinical trial
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Status: Recruiting, Estimated PCD: 2025-03-31
Product
tucatinib
Drug
Trastuzumab
Drug
mFOLFIRINOX
Clinical trial
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2028-11-08
Drug
UTD1
Drug
pembrolizumab
Clinical trial
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
olaparib
Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
Status: Recruiting, Estimated PCD: 2026-03-31
Drug
Ceralasertib
Clinical trial
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2014-07-15
Product
Cixutumumab
Product
OBP-301
Clinical trial
A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma
Status: , Estimated PCD: 2015-03-06
Product
AMG 337
Clinical trial
A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Status: Active (not recruiting), Estimated PCD: 2028-10-30
Clinical trial
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Status: Completed, Estimated PCD: 2022-12-27
Product
Nab-paclitaxel
Clinical trial
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers
Status: Recruiting, Estimated PCD: 2028-01-04
Drug
Devimistat
Drug
Gemcitabine
Product
Hydroxychloroquine
Clinical trial
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS &gt;/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Status: Completed, Estimated PCD: 2015-11-01
Clinical trial
A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Talazoparib
Clinical trial
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Drug
Irinotecan
Clinical trial
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)
Status: Active (not recruiting), Estimated PCD: 2021-03-31
Product
Rucaparib
Product
Berzosertib
Clinical trial
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2022-10-25
Drug
letrozole